Switzerland-based Ferring Pharmaceuticals has announced today that it has acquired Minnesota, US-based Rebiotix, a company focusing on the development of new treatments by obtaining information from patients’ microbiome. The main asset of the acquired company is undoubtedly RBX2660, a new treatment currently undergoing Phase III development in patients with CDI. It has recently obtained a Breakthrough Therapy designation by FDA. Ferring is headquartered in Saint Prex, Switzerland, it is a leader in gastroenterology and has a workforce of approximately 6,500 people globally. The parties have not provided the financial details of the transaction.